Treasury Board of Canada Secretariat
www.tbs-sct.gc.ca
Common menu bar links
Breadcrumb Trail
ARCHIVED - Patented Medicine Prices Review Board
This page has been archived.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Section 3 — Supplementary Information
Financial Highlights
The Patented Medicine Prices Review Board (PMPRB) entered the 2008-2009 facing some financial uncertainties, given the end of its temporary funding, while at the same time the pressures on its ability to fully discharge its mandate were significant. The Board was successful in obtaining approval for increased permanent funding commensurate with its projected workload pressures. Also, the timing of the funding approval required the Board to give primary attention to critical activities such as the continuation of the Guidelines review and the conduct of the price review, investigations and hearings. At the same time, the PMPRB was able to begin important work to enhance its mission- critical database and plan for a retrofit of its facilities to accommodate new FTEs.
The financial highlights presented within this Department Performance Report are intended to serve as a general overview of the PMPRB's financial position and operations. The Board's financial statements can be found on the Board's Web site at http://www.pmprb-cepmb.gc.ca.
($ thousands)
| Condensed Statement of Financial Position At End of Year (March 31, 2009) |
% Change | 2009 | 2008 |
|---|---|---|---|
| ASSETS Total Assets |
(98.9%) | $10.4 | $971.3 |
| LIABILITIES Total Liabilities |
29.2% | $2,068.9 | $1,601.1 |
| EQUITY Total Equity |
226.8% | $2,058.5 | $629.8 |
| TOTAL | (98.9%) | $10.4 | $971.3 |
($ thousands)
| Condensed Statement of Operations At End of Year (March 31, 2009) |
% Change | 2009 | 2008 |
|---|---|---|---|
| EXPENSES Total Expenses |
11.3% | $9,257.7 | $8,316.1 |
| REVENUES Total Revenues |
134.3% | $24,760.0 | $10,566.6 |
| NET COST OF OPERATIONS | 588.8% | ($15,502.3) | ($2,250.5) |
List of Supplementary Information Tables
The following tables are located on the Treasury Board Secretariat Web site at http://www.tbs-sct.gc.ca/dpr-rmr/2008-2009/index-eng.asp
- Table 1: Sources of Non-Respendable Revenue
- Table 9: Green Procurement
Other Items of Interest
PMPRB Annual Report 2008 (http://www.pmprb-cepmb.gc.ca/english/view.asp?x=91&mp=68)
Quarterly NEWSletter (http://www.pmprb-cepmb.gc.ca/english/view.asp?x=287&mp=68)
Patentee's Guide to Reporting (http://www.pmprb-cepmb.gc.ca/english/view.asp?x=146)
Compendium of Guidelines, Policies and Procedures (March 2008)(http://www.pmprb-cepmb.gc.ca/english/view.asp?x=1034)
Compendium of Policies, Guidelines and Procedures, June 2009 (implementation January 1, 2010) http://www.pmprb-cepmb.gc.ca/english/view.asp?x=1206&mp=808
Patent Act (http://laws.justice.gc.ca/en/P-4/index.html)
Patented Medicines Regulations (http://laws.justice.gc.ca/en/P-4/SOR-94-688/index.html)
1. All of the PMPRB's priorities link to the Board's one Strategic Outcome: Canadians and their health care system are protected from excessive pricing for patented medicines sold in Canada and are informed on pharmaceutical trends.
2. A Voluntary Compliance Undertaking (VCU) is a written undertaking by a patentee to adjust the price of a patented drug product to conform to the Excessive Price Guidelines (Guidelines) and to offset excess revenues.
